SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

Nine-month revenue increased 315%, while the company continued to report losses and pursue additional financing alternatives.

Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) reported third-quarter revenue of approximately $2.2 million as it advanced commercialization of its medical devices. Revenue compared with $208,000 a year earlier. Gross margin rose to approximately 62% from 45%, while operating loss narrowed 51% to approximately $1.6 million. Net loss narrowed to $1.595 million from $3.539 million.

Cash totaled $2.005 million at September 30, versus $4.140 million at December 31, 2025. Subsequent exercises of 941,423 Class B warrants at $2.14 per share raised approximately $2.0 million in gross proceeds. SINTX regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement. It completed the limited-use release of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, with initial commercial sales underway, and initiated large-animal studies of silicon nitride-treated medical textiles.

17 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointPost-quarter Class B warrant exercises raised approximately $2.0 million in gross proceeds. 16% of market cap
• Moderate pointThird-quarter revenue increased to approximately $2.2 million from $208,000 a year earlier.
• Moderate pointThird-quarter gross profit increased to $1.362 million from $93,000 a year earlier.
• Moderate pointThird-quarter gross margin increased to approximately 62% from 45%.
• Moderate pointThird-quarter operating loss narrowed 51% to $1.635 million from $3.355 million a year earlier.
• Moderate pointThird-quarter net loss narrowed to $1.595 million from $3.539 million a year earlier.
• Moderate pointNasdaq minimum stockholders’ equity compliance was regained; the requirement is $2.5 million.
• Moderate pointSiNAPTIC Foot & Ankle Osteotomy Wedge System completed limited-use release, with initial commercial sales underway.

9 minor points

• Minor pointThird-quarter operating expenses decreased 13% to $2.997 million from $3.448 million a year earlier.
• Minor pointThird-quarter loss per common share narrowed to $0.24 from $3.46 a year earlier.
• Minor pointNine-month revenue increased 315% to approximately $3.0 million.
• Minor pointNine-month gross profit increased to $1.784 million from $273,000 a year earlier.
• Minor pointNine-month research and development expenses decreased to $1.485 million from $3.618 million a year earlier.
• Minor pointNine-month operating loss narrowed to $7.730 million from $8.403 million a year earlier.
• Minor pointNine-month net loss narrowed to $7.122 million from $8.149 million a year earlier.
• Minor pointNine-month loss per common share narrowed to $1.55 from $6.17 a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.Medical-textile studies initiated; SINTX expects completion in the first quarter of 2027.

Negative

• Major pointExercises of 941,423 Class B warrants at $2.14 per share dilute existing holders.
• Moderate pointCash decreased to $2.005 million at September 30, 2026, from $4.140 million at December 31, 2025.
• Moderate pointCommon shares outstanding increased to 6,886,933 at September 30, 2026, from 3,970,869 at December 31, 2025.
• Moderate pointNine-month general and administrative expenses rose to $7.104 million from $4.836 million a year earlier.
• Minor pointNine-month sales and marketing expenses rose to $812,000 from $100,000 a year earlier.
• Minor pointNine-month results included a $926,000 deemed dividend from warrant modification.

News Explained

The quarter-end share count excludes post-quarter warrant exercises; cash equaled 134.7 days of third-quarter operating outflow at that past rate, not a forward cash estimate.

In reporting third-quarter results, SINTX gives a common-share count of 6,886,933 at September 30, 2026; that quarter-end count predates the post-quarter warrant exercises disclosed in the release.

Compared with 3,970,869 shares outstanding at December 31, 2025, the higher count means each unchanged share represented a smaller portion of common equity at quarter-end.

At September 30, cash was $2.005 million and third-quarter operating cash outflow was $1.369 million; at that past rate, cash equals 134.7 days of outflow, not a forecast.

Sources and calculations

• SINTX third-quarter 2026 results release (2026-11-05)
• SINTX Q3 2026 fundamentals (2026Q3)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $2,005,000 / ($1,369,000 / 92) = 134.7 days

Argus 15 min delay 6 alerts

-0.62% vs previous close $1.61 last price 2.8x rel. volume Open Argus

Details

Market Reaction – SINT

+2.9% Peak in 32 min

$1.51 – $1.80 Day Range

$12.17M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for SINT is 0.62% below the previous close. Argus tracked a peak move of +2.9% during the session. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $1.61. Relative volume is elevated at 2.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Quarterly revenue: Approximately $2.2 million Gross profit: Approximately $1.4 million Gross margin: Approximately 62% +5 more

Quarterly revenue

Approximately $2.2 million

Third quarter 2026, compared with $208,000 in the prior-year period

Gross profit

Approximately $1.4 million

Third quarter 2026, compared with $93,000 in the prior-year quarter

Gross margin

Approximately 62%

Third quarter 2026, compared with 45% in the prior-year quarter

Operating expenses

Decreased 13% to $3.0 million

Third quarter 2026, compared with $3.4 million in the third quarter of 2025

Net loss

Decreased 55% to approximately $1.6 million

Third quarter 2026, compared with $3.5 million in the prior-year quarter

Operating loss

Decreased 51% to $1.6 million

Third quarter 2026, compared with $3.4 million in the third quarter of 2025

Nine-month revenue

Increased 315% to approximately $3.0 million

Nine months ended September 30, 2026

Warrant exercise proceeds

Approximately $2.0 million in gross proceeds

941,423 Class B warrants exercised at $2.14 per share

Historical Context

1 past event · Latest: Oct 01

1 event

1. Oct 01

   revenue update

   24h Move

   -4.5%

   Preliminary Q3 revenue exceeded guidance; final results now report $2.19 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

in vivo, preclinical development, fda-cleared, warrants

4 terms

in vivo medical

"Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

preclinical development medical

"intended to support further preclinical development of potential wound care applications"

Preclinical development is the stage where a potential drug, device, or therapy is tested in the lab and in animals to gather evidence on safety, how it works, and whether it’s worth trying in humans. Investors care because this phase creates early “proof” or warning signs about a candidate’s chances of success—similar to a prototype being stress-tested before production—so results strongly influence a project’s value, timeline, and risk.

fda-cleared regulatory

"Completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

warrants financial

"Received aggregate gross proceeds of approximately $2.0 million from the exercise of 941,423 Class B warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies

SALT LAKE CITY, Utah, Nov. 05, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026.

Third Quarter Financial Results

	●	For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period
	●	Gross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with gross margin increasing to approximately 62% from 45% reflecting improved pricing, higher manufacturing volumes, and increased production efficiencies
	●	Total operating expenses decreased 13% to $3.0 million, compared with $3.4 million in the third quarter of 2025
	●	Net loss decreased 55% to approximately $1.6 million, compared with $3.5 million during the prior-year quarter
	●	Operating loss decreased 51% to $1.6 million, compared with $3.4 million in the third quarter of 2025
	●	For the nine months ended September 30, 2026, total revenue increased 315% to approximately $3.0 million
	●	SINTX ended the third quarter with approximately $2.0 million in cash and cash equivalents and subsequently received approximately $2.0 million in gross proceeds from the exercise of Class B warrants. The Company continues to pursue revenue growth, operating efficiencies, and additional financing alternatives to support operations and commercialization activities.

“Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies,” said Eric Olson, Chief Executive Officer of SINTX.

“The substantial increase in quarterly revenue, combined with significant improvements in gross profit and operating performance, demonstrates the potential of our advanced manufacturing platform as we convert investments over the past several years into revenue-building commercial opportunities. Our industrial business is providing an important commercial foundation as we pursue what we believe are even greater long-term opportunities in healthcare.

“With the initial commercial sales of our SiNAPTIC^® Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market. We also continue to evaluate opportunities to leverage our proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications.

“We believe our performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company. With improving operating performance, expanding commercial activities, and continued investment in our proprietary technologies, we believe SINTX is well positioned to pursue additional growth opportunities in 2027,” concluded Mr. Olson.

Third Quarter and Subsequent 2026 Highlights

	●	Completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, initiated in the first quarter of 2026
	●	Sponsored silicon nitride masterclass with leading orthopedics experts in implant retrieval, biomaterials and clinical practice, to help educate surgeons, develop sales channels and build a disciplined commercial foundation
	●	Regained compliance with Nasdaq’s minimum stockholders’ equity requirement of $2.5 million
	●	Received aggregate gross proceeds of approximately $2.0 million from the exercise of 941,423 Class B warrants at $2.14 per share following the Company’s post-quarter-end call, which was triggered by achieving the third-quarter revenue milestone of $2 million.
	●	Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and wound-healing properties. The studies are expected to be completed in the first quarter of 2027 and are intended to support further preclinical development of potential wound care applications.

The Company will host a conference call and webcast today at 4:30 p.m. ET to review the Company’s third quarter 2026 performance. Management participants will include Eric Olson, Chief Executive Officer and Chairman of the Board, and Kevin Trask, Chief Financial Officer.

Interested parties may access the conference call and webcast as follows:

Webcast: The live webcast will be available on the Events & Presentations page of the Company’s investor relations website at investors.sintx.com and may also be accessed directly here.

Telephone: Analysts and other participants who wish to join by telephone should register in advance using the Conference Call Registration link. Upon registration, participants will receive the dial-in information and a unique PIN.

A replay of the webcast will be available following the call on the Events & Presentations page of the Company’s investor relations website.

About SINTX Technologies, Inc.

Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for medical and other specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC^® Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY^™ technology platform being developed for biocomposite and 3D printing applications.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements include statements regarding continued commercialization and market adoption of its SiNAPTIC^® Foot & Ankle Osteotomy Wedge System; opportunities to leverage its proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications; the anticipated completion, results, and potential applications of ongoing preclinical animal studies evaluating silicon nitride-treated medical textiles for wound care; and advancing specialized medical technologies utilizing its proprietary silicon nitride platform. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. These statements are subject to inherent risks, uncertainties and changes in circumstances that could cause actual results to differ materially from those contemplated or implied by such statements. These risks and uncertainties include the timing and volume of customer orders and product shipments; customer concentration and the potential loss or reduction of business from significant customers; the Company’s ability to maintain or improve manufacturing efficiencies, pricing, and gross margins; uncertainties regarding the timing, completion, and results of preclinical studies; the Company’s ability to secure and execute licensing partnerships; to obtain applicable regulatory clearances or approvals; to protect and enforce its intellectual property; to manufacture products at commercial scale; to obtain sufficient funding; to achieve market acceptance; and to continue as a going concern. Additional risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law, and readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release.

Company Contact:

Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com

SINTX Technologies, Inc.
Condensed Consolidated Balance Sheets – Unaudited
(in thousands, except share and per-share amounts)

		September 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	2,005			$	4,140
Accounts and other receivables, net of allowance for credit losses of $2.0 and $2.4 respectively			131				178
Prepaid expenses and other current assets			829				507
Inventories			2,555				825
Total current assets			5,520				5,650
Inventories			-				219
Property and equipment, net			518				476
Intangible assets, net			116				142
Goodwill			302				302
Operating lease right of use asset			2,213				2,458
Other long-term assets			234				259
Total assets		$	8,903			$	9,506
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	961			$	382
Accrued liabilities			1,190				422
Debt			55				7
Derivative liabilities			345				827
Current portion of operating lease liability			440				398
Other current liabilities			13				1,697
Total current liabilities			3,004				3,733
Operating lease liability, net of current portion			2,509				2,844
Total liabilities			5,513				6,577
Commitments and contingencies
Stockholders’ equity:
Convertible preferred stock Series B, C, D, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 249 total preferred shares issued and outstanding as of September 30, 2026 and December 31, 2025.			-				-
Common stock, $0.01 par value, 250,000,000 shares authorized; 6,937,357 and 4,021,293 shares issued and 6,886,933 and 3,970,869 outstanding as of September 30, 2026 and December 31, 2025, respectively.			69				40
Treasury Stock, 50,424 shares as of September 30, 2026 and December 31, 2025.			(133	)			(133	)
Additional paid-in capital			302,678				295,124
Accumulated deficit			(299,224	)			(292,102	)
Total stockholders’ equity			3,390				2,929
Total liabilities and stockholders’ equity		$	8,903			$	9,506

SINTX Technologies, Inc.
Condensed Consolidated Statements of Operations – Unaudited

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Product revenue		$	2,090			$	150			$	2,837			$	541
Grant and contract revenue			100				58				185				187
Total revenue			2,190				208				3,022				728
Costs of revenue			828				115				1,238				455
Gross profit			1,362				93				1,784				273
Operating expenses:
Research and development			548				1,264				1,485				3,618
General and administrative			2,251				2,102				7,104				4,836
Sales and marketing			140				59				812				100
Grant and contract expenses			58				23				113				122
Total operating expenses			2,997				3,448				9,514				8,676
Loss from operations			(1,635	)			(3,355	)			(7,730	)			(8,403	)
Other income (expenses):
Interest expense			(2	)			(13	)			(16	)			(40	)
Interest income			11				43				45				130
Gain on disposal of equipment			-				-				-				327
Change in fair value of derivative liabilities			-				(214	)			482				(166	)
Other income, net			31				-				97				3
Total other income (expense), net			40				(184	)			608				254
Net loss before income taxes			(1,595	)			(3,539	)			(7,122	)			(8,149	)
Provision for income taxes			-				-				-				-
Net loss		$	(1,595	)		$	(3,539	)		$	(7,122	)		$	(8,149	)
Deemed dividend – warrant modification			-				-				(926	)			-
Deemed dividend – warrant inducement			-				(6,719	)			-				(6,719	)
Net loss attributable to common stockholders		$	(1,595	)		$	(10,258	)		$	(8,048	)		$	(14,868	)
Net loss per share – basic and diluted
Basic – net loss		$	(0.24	)		$	(1.19	)		$	(1.37	)		$	(3.38	)
Basic – attributable to common stockholders		$	(0.24	)		$	(3.46	)		$	(1.55	)		$	(6.17	)
Diluted – net loss		$	(0.24	)		$	(1.19	)		$	(1.37	)		$	(3.38	)
Diluted – attributable to common stockholders		$	(0.24	)		$	(3.46	)		$	(1.55	)		$	(6.17	)
Weighted average common shares outstanding:
Basic			6,665,926				2,963,539				5,186,059				2,411,004
Diluted			6,665,926				2,963,539				5,186,570				2,411,179

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were SINTX’s third-quarter 2026 revenue and net loss?

SINTX reported revenue of approximately $2.2 million and a net loss of $1.595 million for the quarter ended September 30, 2026. A year earlier, revenue was $208,000 and net loss was $3.539 million.

How much did SINTX raise from its post-quarter warrant exercises?

SINTX received approximately $2.0 million in gross proceeds from exercises of 941,423 Class B warrants at $2.14 per share. The exercises followed a post-quarter-end call triggered by achieving the third-quarter revenue milestone of $2 million.

What are SINTX’s medical-textile animal studies testing, and when are they expected to finish?

SINTX expects its large-animal studies of silicon nitride-treated medical textiles to finish in the first quarter of 2027. The studies evaluate sutures and wound dressings for potential antimicrobial, anti-adhesion and wound-healing properties, with the aim of supporting further preclinical development of potential wound care applications.